Semi-Living Cyborg Cells Generate Hope Within the Scientific Medical Community

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide and grow.

“The cyborg cells are programmable, do not divide, and preserve essential cellular activities and gain non-native abilities,” said biomedical engineer Cheemeng Tan from the University of California, Davis.

Biomedical advancements, such as the use of AI and cell therapy, bring with them the potential for myriad applications. One such promising application is the use of cyborg cells in oncology. Lab testing on tissue samples is underway, and the hope is cyborg cells could one day be used to deliver drugs to specific parts of the body.

Where might this technology take science in the coming years? Stephane Budel, Ph.D., a Founding Partner at DeciBio, and Andrew Aijian, Ph.D., a Partner at DeciBio, a strategy and market intelligence company for the precision medicine industry, provided some clues.

Stephane and Andrew’s Thoughts

This is a very exciting paper. The advance of cyborg cells can have several therapeutic applications. A clear one is in oncology. There has been a lot of exciting development recently with CAR Ts. And people are discussing is it going to be autologous cells that come from the patient or allogeneic cells that would be easier to work with, where you would have like a massive batch of cells that you can use.

And there is now a third type of cells you could use: cyber cells. And in this case, you add synthetic polymers. The cells retain a number of functions, but they stop dividing. You can imagine people starting to be looking at a variety of different types of polymers and a variety of different types of synthetic pathways that they do to address cancer cells and beyond.” – Budel

Yeah, this is the first I’ve been exposed to cyborg cells. The first I’m hearing of it. And I think what will be interesting is to see how this approach gets applied to different cell types; bacterial cells, human cells, cells with different functionalities, et cetera. And you can sort of really start to explore a vast space of possibilities and how you can use these types of cells for health applications, synthetic biology, industrial applications, especially if you can introduce non-native capabilities. In the paper, they cited the ability of these cells to be more resistant to peroxide environments, which has implications in industrial applications.

There’s sort of a huge space of functionalities and capabilities that you can explore. And I’m sure that researchers will be spending a lot of time optimizing the cells and the conditions to create many novel functionalities.” –  Aijian

Something we discussed as well is the need for these cells to actually evade the immune system. And there is certainly something that you can engineer in these cells as well that will be important if you want to inject them back into humans to treat virus conditions.” – Budel

Follow us on social media for the latest updates in B2B!

Image

Latest

business insights
Amberd Delivers Real-Time Business Insights, Cutting Executive Reporting From Weeks to Minutes With ADA
February 18, 2026

Many organizations struggle to deliver real-time business insights to executives. Traditional workflows require analysts and database teams to extract, prepare, and validate data before it reaches decision makers. That process can stretch across departments and delay critical answers.. Mazda Marvasti, CEO of Amberd, says the cycle to answer a single business question can take…

Read More
GPU utilization
No Idle GPUs, No Data Leakage: Qumulus Maximizes GPU Utilization for Multiple Customers on Shared Infrastructure
February 18, 2026

Multi-tenant GPU infrastructure is becoming essential as AI deployments scale across customers. Organizations must maximize GPU utilization while maintaining strict data isolation. Idle compute reduces efficiency, yet shared environments can introduce security risks if not designed properly. Mazda Marvasti, CEO of Amberd, says optimizing GPU cycles across multiple customers is essential to maintaining performance…

Read More
AI costs
QumulusAI Brings Fixed Monthly Pricing to Unpredictable AI Costs in Private LLM Deployment
February 18, 2026

Unpredictable AI costs have become a growing concern for organizations running private LLM platforms. Usage-based pricing models can drive significant swings in monthly expenses as adoption increases. Budgeting becomes difficult when infrastructure spending rises with every new user interaction. Mazda Marvasti, CEO of Amberd, says pricing volatility created challenges as his team expanded its…

Read More
GPU infrastructure
Amberd Moves to the Front of the Line With QumulusAI’s GPU Infrastructure
February 18, 2026

Reliable GPU infrastructure determines how quickly AI companies can execute. Teams developing private LLM platforms depend on consistent high-performance compute. Shared cloud environments often create delays when demand exceeds available capacity Mazda Marvasti, CEO of Amberd, says waiting for GPU capacity did not align with his company’s pace. Amberd required guaranteed availability to support…

Read More